| (Values in U.S. Thousands) | Dec, 2020 | Dec, 2019 | Dec, 2018 | Dec, 2017 | Dec, 2016 |
| Sales | 540 | 710 | 1,510 | 610 | 40 |
| Sales Growth | -23.94% | -52.98% | +147.54% | +1,425.00% | unch |
| Net Income | -5,060 | -5,090 | -4,020 | -1,990 | -1,780 |
| Net Income Growth | +0.59% | -26.62% | -102.01% | -11.80% | +58.22% |
Cardax Inc (CDXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Cardax, Inc. is a development stage life sciences company. It develops nutraceutical and pharmaceutical products that provide anti-inflammatory benefits of steroids or NSAIDS. The Company primarily focuses on developing astaxanthin technologies for unmet medical needs. Cardax, Inc. is based in Honolulu, Hawaii.
Fiscal Year End Date: 12/31